Cancers, Vol. 9, Pages 103: Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review
Cancers, Vol. 9, Pages 103: Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review Cancers doi: 10.3390/cancers9080103 Authors: Ryuya Yamanaka Eisuke Abe Toshiteru Sato Azusa Hayano Yasuo Takashima Pituitary adenomas are often treated with radiotherapy for the management of tumor progression or recurrence. Despite the improvement in cure rates, patients treated by radiotherapy are at risk of development of secondary malignancies. We conducted a comprehensive literature review of the secondary intracranial tumors that occurred following radiotherapy to pituitary adenomas to obtain clinicopathological characteristics. The analysis included 48 neuroepithelial tumors, 37 meningiomas, and 52 sarcomas which were published between 1959–2017, although data is missing regarding overall survival and type of irradiation in a significant proportion of the reports. The average onset age for the pituitary adenoma was 37.2 ± 14.4 years and the average latency period before the diagnosis of the secondary tumor was 15.2 ± 8.7 years. Radiotherapy was administered in pituitary adenomas at an average dose of 52.0 ± 19.5 Gy. The distribution of pituitary adenomas according to their function was prolactinoma in 10 (7.2%) cases, acromegaly in 37 (27.0%) cases, Cushing disease in 4 (2.9%) cases, PRL+GH in 1 (0.7%) case, non-functioning adenoma in 57 (41.6%) cases. Irradiation technique delivered was lateral opposing...
The incidence of mouth and throat cancers caused by the human papillomavirus in men has now surpassed the incidence of HPV-related cervical cancers in women.
(Reuters) - A new therapy for a type of lymphoma developed by Kite Pharma, which was acquired by Gilead Sciences Inc, won U.S. approval on Wednesday, marking the second approval for this potentially revolutionary approach to fighting cancer.
U.S. regulators approve 2nd gene therapy for blood cancer, 1st one for adults
The Food and Drug Administration approved a second version of a groundbreaking treatment Wednesday that genetically alters patients' cells to attack cancer — this time, to fight aggressive non-Hodgkin lymphoma. The treatment is for adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other […]Related:Josh Gordon, new director of the National Institute of Mental Health, weighs its futureA 2-year-old’s kidney transplant was put on hold — after his donor father’s probation violationThe mother jailed for refusing to vaccinate he...
Penn State College of Medicine researchers found that textured implants might be more dangerous than smooth implants. They are supposedly more likely to cause breast cancer.
Researchers at the University of Ottawa found five times the amount of cancer-causing chemicals on the skin of firefighters - a higher figure than previously thought - but a shower cut their risk.
A recent study relates future risk to current risk for advanced colorectal cancer. Dr Kerr suggests adding genetic testing to further improve diagnosis.Medscape Oncology
Diagnosis and treatment for any cancer is key to survival, but a new study finds that in the case of melanoma, timing of treatment is critical.
New J. Chem., 2017, Accepted Manuscript DOI: 10.1039/C7NJ03078A, PaperFei Wang, Chuanqi Song, Wei Guo, Dandan Ding, Yan Gao, Qun Zhang, Mei Yan, Chongshen Guo, Shaoqin Liu Being an encouraging approach with high selectivity and minor side-effect, imaging-guided phototherapy for cancer treatment has attracted lots of research interests. Wherein particularly important is development of novel agent that... The content of this RSS Feed (c) The Royal Society of Chemistry
Morrisville-based Novan (Nasdaq: NOVN) is broadening its focus through acquiring new intellectual property rights and is closing in on a deal to move its acne product forward. Through a deal with Know Bio – which was spun out from Novan prior to Novan’s IPO last year – Novan has acquired the exclusive worldwide rights to applications of nitric-oxide-based products for the treatment of cancer-causing viruses. Those viruses include human papillomavirus (HPV)-associa ted sexually transmitted infections. Novan…